Autopsy report · NCT03979664
Iontophoresis in Psoriasis
Cause of deathRegulatory or ethics
“FDA did not provide approval of the use of the drug for the study”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Early Phase 1
- Sponsor
- Wake Forest University Health Sciences
- Sponsor type
- University, hospital or other
- Conditions
- Psoriasis; Psoriasis Vulgaris; Skin Diseases
- Interventions
- Activapatch intellidose 2.5 using active Iontophoresis; Activapatch intellidose 2.5 using inactive Iontophoresis; Dexamethasone
- Participants
- 0
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Topical Cannabidiol Cream and Post-exercise Recovery
“The researchers were not able to acquire funding to initiate the study. Also, the study was not approved by the local IRB which requested a FDA new drug application.” - Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
“FDA request as study could not serve as the confirmatory trial.” - Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK
“Terms could not be met with the FDA.” - Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
“Study Drug was FDA approved Summer 2021” - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
“The study was not approved by the Italian Medicines Agency (AIFA).”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.